Screener
Biogen BIIB Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Biogen’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 6:36 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000875045-26-000075
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Equity: | ||
| Biogen Inc. shareholders’ equity: | ||
| Preferred stock, par value $0.001 per share | — | — |
| Common stock, par value $0.0005 per share | 0.1 | 0.1 |
| Additional paid-in capital | 983.0 | 863.1 |
| Accumulated other comprehensive income (loss) | (127.7) | (182.0) |
| Retained earnings | 20,969.7 | 20,552.7 |
| Treasury stock, at cost | (2,977.1) | (2,977.1) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Biogen's common stock, par value (in dollars per share)?
- Biogen (BIIB) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
- How has Biogen's common stock, par value (in dollars per share) changed year-over-year?
- Biogen's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Biogen's common stock, par value (in dollars per share)?
- Over 3 years (2020 to 2023), Biogen's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
Ask your AI about Biogen's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude